
Sign up to save your podcasts
Or


FDA’s removal of GLP-1 drugs from the shortage list ends supplemental compounding, shifting patient access back to branded semaglutide and tirzepatide.
Featuring: Sara Heath, executive editor, Xtelligent Healthcare
Alivia Kaylor, senior editor of Pharma Life Sciences, Xtelligent Healthcare
In today’s episode, we’ll cover…
and more!
References:
To learn more about GLP-1s, check out our Pharma Life Sciences and Patient Engagement sites.
By Informa TechTarget4.7
3434 ratings
FDA’s removal of GLP-1 drugs from the shortage list ends supplemental compounding, shifting patient access back to branded semaglutide and tirzepatide.
Featuring: Sara Heath, executive editor, Xtelligent Healthcare
Alivia Kaylor, senior editor of Pharma Life Sciences, Xtelligent Healthcare
In today’s episode, we’ll cover…
and more!
References:
To learn more about GLP-1s, check out our Pharma Life Sciences and Patient Engagement sites.

30,706 Listeners

112,037 Listeners

8,349 Listeners

1,039 Listeners

94 Listeners

28 Listeners

29,164 Listeners

19,641 Listeners

14 Listeners